Semaglutide 7mg GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist that has been extensively studied for its effects on glucose regulation, appetite signalling and body-weight management. Research and approved medicines containing semaglutide have evaluated its role in type 2 diabetes and chronic weight management.

Research areas include: GLP-1 receptor signalling, glucose metabolism, appetite regulation, body-weight regulation, insulin secretion and cardiometabolic health. The specific 7mg self-mix vial formulation shown here is not equivalent to an approved commercial semaglutide product, and its safety, quality and efficacy would need to be established separately.

Important: Semaglutide is a regulated prescription medicine, and the specific self-mix product shown here is not established as a SAHPRA-approved formulation. SAHPRA specifically warns about unregistered and compounded semaglutide products and notes that powder/self-mix GLP-1 products should be treated with caution. This description is for research/informational purposes and is not intended to diagnose, treat, cure or prevent any disease or medical condition.

The Certificate of Analysis for lot GX-2026 confirms an HPLC purity of 99%+ and identity confirmed by mass spectrometry.

The Safety Data Sheet describes handling, storage and disposal information for this research compound. Always follow standard laboratory safety practice.